Insmed Presents Positive Data on Anti-Cancer Drug Candidate to San Antonio Breast Cancer Symposium
RICHMOND, Va.--(BUSINESS WIRE)--Dec. 3, 2003--Insmed Incorporated (Nasdaq-NMS: INSM) (Nasdaq: INSM) reported today that data from recent studies of the Company's proprietary anti-cancer compound, recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3), will be presented at The 26th Annual San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzalez Convention Center, San Antonio, Texas, December 3 - 6.
These studies conducted in the laboratory of Dr. Brian Leyland-Jones of McGill University were designed to explore the ability of rhIGFBP-3 to sensitize breast cancer cells to Herceptin® (Trastuzumab).
The results of this study, published in the abstract titled, "Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer", demonstrated the following:
- In Herceptin resistant breast carcinoma cells there was an increased level of insulin-like growth factor receptor.
- rhIGFBP-3 caused dose dependent inhibition of Herceptin resistant breast carcinoma growth.
- rhIGFBP-3 in combination with Herceptin caused a dose dependent increase in sensitivity of breast carcinoma cells to Herceptin.
Please view the abstract and poster being presented:
Go to www.insmed.com
Click on "Product Pipeline"
Click on the cancer development timeline arrow
For reprints, please contact, Baxter Phillips, at 804.565.3041 or firstname.lastname@example.org.
IGFBP-3: A Naturally Occurring Anti-Cancer Agent
Our proprietary product, rhIGFBP-3, is a protein that is normally found in our bloodstream that has been shown to induce cancer cell death in a variety of experimental systems. Several studies have demonstrated that cancer risk increases with decreasing levels of circulating IGFBP-3. In addition, recent independent studies have demonstrated that IGFBP-3 can induce cell cycle arrest and enhance the efficacy of chemotherapeutic agents. Insmed is currently engaged in an active preclinical program with leading clinical oncologists and world experts in the field of IGFBP-3 research to evaluate the efficacy of rhIGFBP-3 as a therapeutic agent and to define the optimal clinical protocol in which to translate these promising observations into human clinical trials.
Insmed Incorporated develops pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs. The Company's most advanced product candidate, the rhIGF-I/rhIGFBP-3 complex is a novel delivery composition of IGF-I that regulates essential metabolic and anabolic (growth promoting) processes, such as glucose uptake and tissue regeneration. Insmed is currently in a pivotal Phase III clinical trial for the rhIGF-I/rhIGFBP-3 complex for the treatment of Growth Hormone Insensitivity Syndrome (GHIS). The Company's second product candidate, rhIGFBP-3, is a recombinant protein that is being developed as an anti-cancer agent targeted towards the inhibition of solid tumor growth. Further information is available at the company's corporate website: www.insmed.com
Herceptin® is the first humanized antibody approved for the treatment of HER2 positive metastatic breast cancer. Herceptin® is designed to target and block the function of HER2 protein overexpression. Herceptin® is a registered trademark of Genentech (NYSE: DNA).
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
CONTACT: Insmed Incorporated
Baxter Phillips, III, 804-565-3041